teaser
The race to get a new class of oral anticoagulants onto the market may be being led by Bayer and Johnson & Johnson’s rivaroxaban, but Bristol-Myers Squibb and Pfizer’s apixaban may not be too far behind.
B-MS has just made public positive phase II data for apixaban, a new, direct-acting inhibitor of coagulation factor Xa, which was evaluated in patients with confirmed deep-vein thrombosis.
According to the data, presented at the International Society on Thrombosis and Haemostasis meeting in Geneva, 520 patients were allocated to one of three groups
